SCHEMBL25898026

SCHEMBL25898026

Cc1nnc(-c2ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCC(N)=O)cc2)nn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RARB P10826 2/20 0.45
▸ L3MBTL1 Q9Y468 4/20 0.43
▸ PARP10 Q53GL7 1/20 0.39
▸ MAPT P10636 3/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ KDM4E B2RXH2 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ THRA P10827 1/20 0.38
▸ CHEK1 O14757 1/20 0.38
▸ RARA P10276 1/20 0.38
▸ CHEK2 O96017 1/20 0.37
▸ PRSS1 P07477 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25897953 1.00 RARB (0.45) RARBL3MBTL1PARP10MAPTNPSR1
SCHEMBL25623345 0.88 L3MBTL1 (0.51) RARBL3MBTL1MAPTNPSR1KDM4E
SCHEMBL17721288 0.88 L3MBTL1 (0.51) RARBL3MBTL1MAPTNPSR1KDM4E
SCHEMBL25427287 0.88 L3MBTL1 (0.51) RARBL3MBTL1MAPTNPSR1KDM4E
SCHEMBL25623340 0.88 L3MBTL1 (0.51) RARBL3MBTL1MAPTNPSR1KDM4E
SCHEMBL22895274 0.83 RARB (0.53) RARBL3MBTL1KDM4EALDH1A1SMN1; SMN2
SCHEMBL21787229 0.82 CDK5 (0.46) RARBL3MBTL1KDM4ESMN1; SMN2NPC1
SCHEMBL25671670 0.82 CDK5 (0.46) RARBL3MBTL1KDM4ESMN1; SMN2NPC1
SCHEMBL25894407 0.81 RARB (0.45) RARBL3MBTL1MAPTNPSR1KDM4E
SCHEMBL21125363 0.80 L3MBTL1 (0.46) RARBL3MBTL1MAPTNPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230235082-A1 SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) 2023-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230235082-A1 SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME FUT5, FUT6, SIGLEC7 RARB 4725/4885L3MBTL1 2801/4885PARP10 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback